Nova Eye Medical (EYE) Discussion, page-2624

That's the thing, investors know what we have here. We keep up to date on LinkedIn updates, conferences and the ophthalmology news sites and so we can see how much traction iTrack Advance is getting in the market, and how popular of a device it is. Not to mention other drivers such as the rapidly increasing popularity of interventional glaucoma management and increasing awareness of how bad drops are. We see this because we are invested already and are actively keeping up to date on the news and developments, however non-existing investors won't become aware of this until it is either announced or reflected eventually in the financials. As a result of this significant information asymmetry we have a situation where we have an incredibly tightly held stock by investors who are not willing to sell so cheap based on our knowledge of how well this company is performing, however we don't yet have a sufficient number of buyers aware about this stock to push this sky high, and we won't until EYE can get some more announcements out showing non-existing investors just how strong they're performing. It's pretty obvious though that given how tightly held this is, it won't take much buying volume to really push it quite high. The company just needs to get this appearing on more radars.